Non-alcoholic fatty liver disease laboratory findings

Jump to navigation Jump to search

Non-Alcoholic Fatty Liver Disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Non-alcoholic fatty liver disease laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non-alcoholic fatty liver disease laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non-alcoholic fatty liver disease laboratory findings

CDC on Non-alcoholic fatty liver disease laboratory findings

Non-alcoholic fatty liver disease laboratory findings in the news

Blogs on Non-alcoholic fatty liver disease laboratory findings

Directions to Hospitals Treating Non-alcoholic fatty liver disease

Risk calculators and risk factors for Non-alcoholic fatty liver disease laboratory findings

Editor in Chief: Elliot Tapper, M.D., Beth Israel Deaconess Medical Center, C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Elevated liver function tests are common. Typically, one finds a 2-4 fold elevation of the ALT above the normal limit and an ALT/AST ratio of greater than 1.This ratio is imperfect, as AST tends to rise with the degree of fibrosis. The Ratio of Aspartate Aminotransferase to Alanine Aminotransferase: Potential Value in Differentiating Nonalcoholic Steatohepatitis From Alcoholic Liver disease.Furthermore, high ALT values within the reference range (less than 40 IU) are still predictive of NAFLD/NASH. Higher Concentrations of Alanine Aminotransferase within the Reference Interval Predict Nonalcoholic Fatty Liver Disease.Another blood test that can be elevated is the ferritin. Typically, and except in very advanced disease, the liver's synthetic function is intact with normal albumin and INR.

When considering NAFLD, other tests are generally performed, including those for associated conditions (e.g. glucose, hemoglobin A1C) and those to distinguish this disease from viral hepatitis. Additionally, autoimmune causes are ruled out with serology. TSH is warranted, as hypothyroidism is more prevalent in NASH patients.

Laboratory Findings

  • There is no significant diagnostic laboratory findings associated with NAFLD.
  • An elevated concentration of serum aspartate transaminase (AST) and alanine transaminase (ALT) is not reliable for the diagnostic of NAFLD.
  • Ultrasound(USG), computer tomography (CT) and magnetic resonance imaging (MRI) are usually not a reliable approach to diagnosis for patients with NAFLD.

NAFLD activity score (NAS)

STEATOSIS S SCORE COMMENT
<5% 0 Refers to the quantity of surface area involved by means of steatosis as evaluated on low to medium power examination; minimum steatosis (<5%) gets a rating of 0 to keep away from giving excess weight to biopsies with little or no fatty change.[1]
5–33% 1
34–66% 2
>66% 3
Lobular Inflammation L SCORE
None 0 Acidophil bodies are not protected by this evaluation, neither is the portal irritation.[2]
<2 foci 1
2–4 foci 2
>4 foci 3
Hepatocyte Balloning B score
None 0
Few ballooned cells 1 The term "few" means rare however specific ballooned hepatocytes as well as cases which are diagnostically borderline.
Many ballooned cells 2 Maximum cases with distinguished ballooning additionally had Mallory's hyaline, howeverMallory's hyaline isn't scored one after the other for the NAS

.

References

  1. Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
  2. "Transplant Pathology Internet Services".

Template:WS Template:WH